Lv1
60 积分 2024-08-19 加入
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
2天前
已完结
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
4个月前
已完结
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
6个月前
已完结
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
6个月前
已完结
Incidence and prevalence of systemic lupus erythematosus in urban China, 2013–2017: A nationwide population-based study
7个月前
已完结
The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China
8个月前
已完结
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation
8个月前
已完结
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
8个月前
已完结
Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study
8个月前
已完结
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
10个月前
已完结
皖公网安备34019202002308
